Abstract | AIM: MATERIAL AND METHODS: The treatment effectiveness according to the international criteria of complete and partial remission was assessed in 37 patients with progressive, splenic, tumor and bone marrow forms of CLL given 5-day courses of fludarabine in a single daily dose 25 mg. RESULTS: In progressive CLL, the remission was achieved in 45% of the patients (10% complete and 35% partial), in splenic form--62.5% (12.5% complete, 50% partial), in tumor form--50% (100% partial). In bone marrow form no remissions were obtained. CONCLUSION:
Fludarabine is effective in therapy of pretreated CLL patients. The treatment should be adjusted to CLL form.
|
Authors | N G Gabeeva, A V Pivnik, T N Moiseeva, E E Zybunova, R S Samoĭlova, A M Kremenetskaia, E Iu Varlamova, I B Kaplanskaia |
Journal | Terapevticheskii arkhiv
(Ter Arkh)
Vol. 72
Issue 8
Pg. 42-5
( 2000)
ISSN: 0040-3660 [Print] Russia (Federation) |
Vernacular Title | Fliudarabin v lechenii khronicheskogo limfoleĭkoza. |
PMID | 11019427
(Publication Type: Comparative Study, English Abstract, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Vidarabine
- fludarabine
|
Topics |
- Adult
- Antineoplastic Agents
(administration & dosage)
- Bone Marrow
(pathology)
- Disease Progression
- Female
- Humans
- Injections, Intravenous
- Leukemia, Lymphocytic, Chronic, B-Cell
(drug therapy, pathology)
- Male
- Middle Aged
- Remission Induction
- Retrospective Studies
- Vidarabine
(administration & dosage, analogs & derivatives)
|